	US 12,435,379 B2
	BTK mutation and ibrutinib resistance
Y. Lynn Wang, Chicago, IL (US)
Assigned to The University of Chicago, Chicago, IL (US)
Filed by The University of Chicago, Chicago, IL (US)
Filed on Aug. 11, 2021, as Appl. No. 17/399,831.
Application 17/399,831 is a continuation of application No. 16/302,015, granted, now 11,118,233, previously published as PCT/US2017/033354, filed on May 18, 2017.
Claims priority of provisional application 62/338,311, filed on May 18, 2016.
Prior Publication US 2022/0090208 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12N 9/12 (2006.01); C12Q 1/6886 (2018.01); G01N 33/573 (2006.01)

CPC C12Q 1/6886 (2013.01) [C12N 9/12 (2013.01); G01N 33/573 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/912 (2013.01); G01N 2800/52 (2013.01)]

3 Claims

1. A composition comprising (1) a cDNA molecule encoding a mutant BTK polypeptide comprising a threonine to alanine modification at position corresponding to position 316 of the sequence set forth in SEQ ID NO: 1 and (2) a cDNA molecule encoding a BTK polypeptide without a threonine to alanine modification at position corresponding to position 316 of the sequence set forth in SEQ ID NO: 1, wherein the cDNA molecules comprise exon-exon junctions.